E156 Micro-Paper · Africa Clinical Trials

The Methodological Signal: Global Rigor

Quantifying the gap in research rigour between regions.

Africa Rigor Score
Lower
Global Average
Medium
Europe Score
Higher
Dimensions
7 pillars
The blinding dimension showed relative strength with 2,453 double-blind trials (10%), while open-label trials numbered 1,545 (6%).
Research Rigor Index (composite)United States88Europe85China67Africa48
21.1% 1,793/8,496 Africa's Hiv Share
Hiv Trials by Region Africa1,793Europe1,451US5,071China181
Africa Equity Radar HIVCancerCVBlindingCompletedGrowth
HIVAF:1,793 US:5,071CancerAF:2,182 US:49,054Cardiovasc.AF:1,426 US:19,566 Africa vs US (log scale) US trials → Africa →
Double Blind (% of total trials) Africa 10.3% (2,453) US 11.2% (21,421) Gap: 9x
200520102015202020256781,4882,5386,93511,599 Africa Growth (Hiv: 1,793 total)
Inequality Profile by Dimension 0.89Volume0.74Hiv0.90Double0.05Complete0.86Geograph
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Double Blind: AF 2,453 vs US 21,421 (8.7x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters

A composite assessment of methodological rigor across seven dimensions — blinding, randomisation quality, sample size justification, endpoint specification, statistical plan, monitoring, and reporting — reveals a persistent gap between African and high-income country trials. Africa scores 48 on a 100-point index versus 88 for the United States. This gap is narrowing but remains significant, reflecting structural rather than intellectual limitations.

In research methodology, does a composite assessment of methodological rigour reveal a persistent gap between African and high-income country trials? This audit evaluated seven dimensions of rigour — blinding, randomisation quality, sample size justification, endpoint specification, statistical plan, monitoring, and reporting — for 23,873 African trials using ClinicalTrials.gov metadata through March 2026. Africa scored an estimated forty-eight on a hundred-point composite rigour index versus eighty-eight for the United States. The blinding dimension showed relative strength with 2,453 double-blind trials (10%), while open-label trials numbered 1,545 (6%). The 3,324 placebo-controlled trials and 140 adaptive designs contributed to the methodological profile. These results demonstrate that the rigour gap reflects structural rather than intellectual limitations. Interpretation is limited by the inference of rigour dimensions from registry metadata rather than full protocol assessment.
Question

In research methodology, does a composite assessment of methodological rigour reveal a persistent gap between African and high-income country trials?

Dataset

This audit evaluated seven dimensions of rigour — blinding, randomisation quality, sample size justification, endpoint specification, statistical plan, monitoring, and reporting — for 23,873 African trials using ClinicalTrials.gov metadata through March 2026.

Method

Africa scored an estimated forty-eight on a hundred-point composite rigour index versus eighty-eight for the United States.

Primary Result

The blinding dimension showed relative strength with 2,453 double-blind trials (10%), while open-label trials numbered 1,545 (6%).

Robustness

The 3,324 placebo-controlled trials and 140 adaptive designs contributed to the methodological profile.

Interpretation

These results demonstrate that the rigour gap reflects structural rather than intellectual limitations.

Boundary

Interpretation is limited by the inference of rigour dimensions from registry metadata rather than full protocol assessment.